Related Experiment Video

Updated: Apr 6, 2026

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

3.2K

Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on β1 and β2-adrenergic receptors

Olga Vriz1, Rosalba Minisini2, Concetta Zito3

  • 1Department of Emergency and Cardiology, S. Antonio Community Hospital, San Daniele del Friuli (UD), Italy.

International Journal of Cardiology
|July 22, 2015
PubMed

Insights

Genetic variations in beta-adrenoceptors differ between tako-tsubo cardiomyopathy patients and healthy individuals. However, these receptor polymorphisms are similar between tako-tsubo cardiomyopathy and ST-elevation myocardial infarction patients.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Tako-tsubo cardiomyopathy (TTC) shares pathophysiological mechanisms with ST-elevation myocardial infarction (STEMI), involving catecholamine excess and sympathetic overstimulation.
  • Adrenoceptors, particularly beta-1 (β1) and beta-2 (β2), are key mediators of sympathetic activity and are implicated in cardiac function and disease.

Purpose of the Study:

  • To investigate the distribution of allelic variants of β1- and β2-adrenoceptors in patients with TTC.
  • To compare adrenoceptor polymorphisms between TTC patients, anterior STEMI patients, and healthy control subjects.
  • To identify potential genetic predispositions or differences in adrenoceptor function related to TTC.

Main Methods:

  • Genotype frequencies of β1-adrenoceptor (Gly389Arg) and β2-adrenoceptor (Arg16Gly, Gln27Glu) polymorphisms were analyzed.
  • A cohort of 97 TTC patients, 81 anterior STEMI patients, and 101 controls were included in the study.
  • Statistical analysis, including the Pearson chi-squared test and post-hoc analysis, was employed to assess differences in genotype frequencies.

Main Results:

  • Significant differences in genotype frequencies for β1-adrenoceptor (Gly389Arg) and β2-adrenoceptor (Arg16Gly, Gln27Glu) polymorphisms were observed among the combined groups (TTC, STEMI, controls).
  • Post-hoc analysis revealed no statistically significant differences in these adrenoceptor polymorphisms when comparing TTC patients directly with anterior STEMI patients.
  • Anterior STEMI patients exhibited a worse cardiovascular risk factor profile, including higher prevalence of hypertension, diabetes, and coronary artery disease, compared to TTC patients.

Conclusions:

  • β-adrenoceptor polymorphisms in TTC patients were found to differ from those in normal subjects.
  • No significant differences in β-adrenoceptor polymorphisms were identified between TTC patients and anterior STEMI patients.
  • Distinct cardiovascular risk factor profiles exist between TTC and anterior STEMI patient groups, despite similarities in adrenoceptor genetics.
Abstract

Keywords:
ST-elevation myocardial infarctionTako-tsubo cardiomyopathyβ-Adrenoceptor polymorphisms

More Related Videos

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

4.5K
Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts09:29

Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts

Published on: March 22, 2017

7.9K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.5K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.3K
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
5.7K